GSK2126458 (Omipalisib, GSK458, GSK-458, GSK-2126458)是可口服的PI3K选择性抑制剂，作用于p110α/β/γ/δ时K_i分别为0.019、0.13、0.024和0.06 nM，能抑制细胞增殖，具有抗肿瘤活性。

参考文献

[1] Knight SD, et al. Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. ACS Med. Chem. Lett. 2010 Jan 19;1(1):39-43.

[2] Greger JG, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012 Apr;11(4):909-20.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。